Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6074, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB) plans to procure on a sole source basis services to provide analysis of samples for comparison of the presence of Sex Steroid Hormones in relation to primary liver cancer, specifically hepatocellular carcinoma (HCC) from the Universite Laval, Pavillion Des Sciences De L'education; Room 1434; 2320 Rue Des Bibliotheques; Quebec; QC; G1V 0A6, CAN. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 and the business size standard is $12.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI), National Institutes of Health (NIH) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. Experimental animal studies have supported a role for hormones in the etiology of hepatocellular carcinoma (HCC), but whether hormones are also related to HCC in humans is not clear. In studies conducted in Taiwan, a positive association between testosterone levels and HCC among men infected with HBV was found. In contrast, a study from Shanghai found that men infected with HBV had significantly higher testosterone levels than uninfected men and that this relationship examined the testosterone-HCC relationship. Prospective data from other cohorts, including studies of populations where HBV is not a risk factor, have not been reported. Similarly, no studies have yet examined the relationship of estrogens in men and development of HCC. To examine the relationship between androgens and estrogens and the development of HCC, the NCI will compare hormone levels in pre-diagnostic samples of men who subsequently developed and in control men from the Kaiser-Oakland MHC cohort study. Sera from 100 men who developed HCC and 100 men who did not develop HCC will be included, as will 10% QC samples (N=20) for a total of 220 samples. The contractor shall test a total of 200 samples and 20 controls for quantitation of the following sex steroid hormones and protein: i. Dehydroepiandrosterone (DHEA) using GC-MS ii. Androst-5-enediol (Delta-5diol) using GC-MS iii. Androstenedione (4-dione) using GC-MS iv. Testosterone (T) using GC-MS v. Dihydrotestosterone (DHT) using GC-MS vi. Androsterone (ADT) using GC-MS vii. Estrone (E1) using GC-MS viii. Estradiol (E2) using GC-MS ix. Androsterone glucuronide using LC-MSMS x. 3-androstanediol-17 glucuronide using LC-MSMS xi. 3-androstanediol-3 glucuronide using LC-MSMS xii. DHEA-sulfate using LC-MSMS xiii. Estrone sulfate using LC-MSMS xiv. Sex Hormone Binding Globulin (SHBG; protein) using ELISA Laval University is the only known laboratory that can quantitate all13 sex steroid hormones and SHBG using gold standard technologies (GC-MS or LC-MSMS for each hormone analyte, and ELISA for SHBG) using a total volume-for all assays combined-of just 0.85 ml of serum per patient, with coefficients of variations less than 10% for each analyte. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on August 10, 2012. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed
+1 (555) 000-0000 or emailed to Terry Galloway, Contract Specialist at
contact@example.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120132-TG on all correspondence.
